BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 15604213)

  • 21. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
    Pospisilik JA; Martin J; Doty T; Ehses JA; Pamir N; Lynn FC; Piteau S; Demuth HU; McIntosh CH; Pederson RA
    Diabetes; 2003 Mar; 52(3):741-50. PubMed ID: 12606516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
    Nagakura T; Yasuda N; Yamazaki K; Ikuta H; Tanaka I
    Metabolism; 2003 Jan; 52(1):81-6. PubMed ID: 12524666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men.
    Carr RD; Larsen MO; Jelic K; Lindgren O; Vikman J; Holst JJ; Deacon CF; Ahrén B
    J Clin Endocrinol Metab; 2010 Feb; 95(2):872-8. PubMed ID: 20008019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of stimulators such as GLP-1, PACAP, and nicotinamide on glucose-stimulated insulin secretion from porcine pancreatic endocrine cells in long-term culture.
    Sato A; Wang PC; Ohgawara H
    Pancreas; 2002 Jul; 25(1):86-93. PubMed ID: 12131777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
    Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
    J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
    Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
    Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F; Fehmann HC; Göke R; Göke B
    Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
    Mentlein R; Gallwitz B; Schmidt WE
    Eur J Biochem; 1993 Jun; 214(3):829-35. PubMed ID: 8100523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations.
    Deacon CF; Plamboeck A; Rosenkilde MM; de Heer J; Holst JJ
    Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E468-75. PubMed ID: 16608883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
    O'Harte FP; Mooney MH; Kelly CM; McKillop AM; Flatt PR
    Regul Pept; 2001 Jan; 96(3):95-104. PubMed ID: 11111014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DPP-4 inhibition increases GIP and decreases GLP-1 incretin effects during intravenous glucose tolerance test in Wistar rats.
    Freyse EJ; Berg S; Kohnert KD; Heinke P; Salzsieder E
    Biol Chem; 2011 Mar; 392(3):209-15. PubMed ID: 21281062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucose dependence of insulinotropic actions of pituitary adenylate cyclase-activating polypeptide in insulin-secreting INS-1 cells.
    Rosengren A; Filipsson K; Jing XJ; Reimer MK; Renström E
    Pflugers Arch; 2002 Jul; 444(4):556-67. PubMed ID: 12136276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucagon-like peptide-1 is a physiological incretin in rat.
    Wang Z; Wang RM; Owji AA; Smith DM; Ghatei MA; Bloom SR
    J Clin Invest; 1995 Jan; 95(1):417-21. PubMed ID: 7814643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.
    Gautier JF; Fetita S; Sobngwi E; Salaün-Martin C
    Diabetes Metab; 2005 Jun; 31(3 Pt 1):233-42. PubMed ID: 16142014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
    Parkes DG; Pittner R; Jodka C; Smith P; Young A
    Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic stimulatory effect of glucagon-like peptide-1 (7-36) amide and glucose-dependent insulin-releasing polypeptide on the endocrine rat pancreas.
    Fehmann HC; Göke B; Göke R; Trautmann ME; Arnold R
    FEBS Lett; 1989 Jul; 252(1-2):109-12. PubMed ID: 2668027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.